The Role of Central Laboratories in AD Trials

Dec 4, 2013

Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that mainly affects the elderly population. The prevalence of AD is predicted to increase to 115.4 million by 2050. Tatiana Souslova at ACM Global Central Lab looks into why despite having the first ...

Read More